ILUMYA(r) (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
· newswise.com · popularity 16/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at newswise.com →
Summary
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA(r) (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 16.